Judge Cuts Some Of Atum's Claims In Gene Therapy IP Row
A Massachusetts federal judge has trimmed biotechnology company Atum's fraud and mismanagement counterclaims in rival SalioGen's trade secrets suit against it over genomics technology, but allowed Atum's arguments over the ownership...To view the full article, register now.
Already a subscriber? Click here to view full article